GEP20267875B - Processes for the preparation of a kinase inhibitor - Google Patents
Processes for the preparation of a kinase inhibitorInfo
- Publication number
- GEP20267875B GEP20267875B GEAP202516101A GEAP2025016101A GEP20267875B GE P20267875 B GEP20267875 B GE P20267875B GE AP202516101 A GEAP202516101 A GE AP202516101A GE AP2025016101 A GEAP2025016101 A GE AP2025016101A GE P20267875 B GEP20267875 B GE P20267875B
- Authority
- GE
- Georgia
- Prior art keywords
- processes
- preparation
- kinase inhibitor
- formula
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B43/00—Formation or introduction of functional groups containing nitrogen
- C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063017739P | 2020-04-30 | 2020-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GEP20267875B true GEP20267875B (en) | 2026-03-25 |
Family
ID=76076455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GEAP202516101A GEP20267875B (en) | 2020-04-30 | 2021-04-30 | Processes for the preparation of a kinase inhibitor |
Country Status (27)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| AR127561A1 (es) * | 2021-11-03 | 2024-02-07 | Exelixis Inc | Compuestos para el tratamiento de trastornos dependientes de cinasas |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1154105A (zh) | 1994-06-08 | 1997-07-09 | H·隆德贝克有限公司 | 4-芳基-1-(二氢化茚甲基、二氢苯并呋喃甲基或二氢苯并噻吩甲基)哌啶、-四氢吡啶或哌嗪类化合物 |
| ZA954689B (en) | 1994-06-08 | 1996-01-29 | Lundbeck & Co As H | 4-Aryl-1-(indanmethyl dihydrobenzofuranmethyl or dihydrobenzothiophenemethyl) piperidines tetrahydropyridines or piperazines |
| SMP200900002B (it) | 2006-06-12 | 2010-01-19 | Novartis Ag | Sali di n-idrossi-3-[4-[[[2-(2-metil-1h-indol-3-il)etil]ammino]metil]fenil]-2e-2-propenammide |
| CN101466672B (zh) | 2006-06-12 | 2012-05-16 | 诺瓦提斯公司 | N-羟基-3-[4-[[[2-(2-甲基-1h-吲哚-3-基)乙基]氨基]甲基]苯基]-2e-2-丙烯酰胺的盐 |
| CA2743416A1 (en) * | 2008-11-13 | 2010-05-20 | Exelixis Inc. | Methods of preparing quinoline derivatives |
| TW201920110A (zh) * | 2009-01-16 | 2019-06-01 | 美商艾克塞里克斯公司 | 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途 |
| WO2012009722A1 (en) * | 2010-07-16 | 2012-01-19 | Exelixis, Inc. | C-met modulator pharmaceutical compositions |
| PL2768796T3 (pl) | 2011-10-20 | 2020-05-18 | Exelixis, Inc. | Sposób wytwarzania pochodnych chinoliny |
| EA033834B1 (ru) | 2014-07-31 | 2019-11-29 | Exelixis Inc | Способ получения кабозантиниба, меченного фтором-18, и его аналогов |
| AU2019212800B2 (en) | 2018-01-26 | 2024-05-23 | Exelixis, Inc. | Compounds for the treatment of kinase-dependent disorders |
| SG11202006945PA (en) | 2018-01-26 | 2020-08-28 | Exelixis Inc | Compounds for the treatment of kinase-dependent disorders |
| HRP20251184T1 (hr) * | 2018-01-26 | 2025-12-05 | Exelixis, Inc. | Spojevi za liječenje poremećaja ovisnih o kinazi |
| PL3894012T4 (pl) * | 2018-12-13 | 2026-01-05 | Exelixis, Inc. | Postacie krystaliczne i postacie soli inhibitora kinazy |
| CN109761899B (zh) * | 2019-02-14 | 2022-11-15 | 广州六顺生物科技股份有限公司 | 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物 |
-
2021
- 2021-04-30 FI FIEP21727657.5T patent/FI4143169T3/fi active
- 2021-04-30 DK DK21727657.5T patent/DK4143169T3/da active
- 2021-04-30 LT LTEPPCT/US2021/030035T patent/LT4143169T/lt unknown
- 2021-04-30 MA MA59466A patent/MA59466B1/fr unknown
- 2021-04-30 TW TW110115786A patent/TWI887405B/zh active
- 2021-04-30 MX MX2022013528A patent/MX2022013528A/es unknown
- 2021-04-30 SI SI202130435T patent/SI4143169T1/sl unknown
- 2021-04-30 JP JP2022566135A patent/JP7728795B2/ja active Active
- 2021-04-30 US US17/922,208 patent/US12497367B2/en active Active
- 2021-04-30 CA CA3176042A patent/CA3176042A1/en active Pending
- 2021-04-30 KR KR1020227037607A patent/KR20230005190A/ko active Pending
- 2021-04-30 AU AU2021263474A patent/AU2021263474A1/en active Pending
- 2021-04-30 PT PT217276575T patent/PT4143169T/pt unknown
- 2021-04-30 PH PH1/2022/552821A patent/PH12022552821A1/en unknown
- 2021-04-30 CN CN202180031136.7A patent/CN115461328B/zh active Active
- 2021-04-30 CR CR20220551A patent/CR20220551A/es unknown
- 2021-04-30 WO PCT/US2021/030035 patent/WO2021222673A1/en not_active Ceased
- 2021-04-30 EP EP21727657.5A patent/EP4143169B1/en active Active
- 2021-04-30 RS RS20260593A patent/RS68116B1/sr unknown
- 2021-04-30 BR BR112022021712A patent/BR112022021712A2/pt unknown
- 2021-04-30 GE GEAP202516101A patent/GEP20267875B/en unknown
- 2021-04-30 HR HRP20260608TT patent/HRP20260608T1/hr unknown
- 2021-04-30 PE PE2022002513A patent/PE20230110A1/es unknown
- 2021-04-30 SM SM20260219T patent/SMT202600219T1/it unknown
- 2021-04-30 CN CN202511511945.4A patent/CN121591655A/zh active Pending
-
2022
- 2022-10-26 IL IL297684A patent/IL297684B2/en unknown
- 2022-10-26 CO CONC2022/0015205A patent/CO2022015205A2/es unknown
- 2022-10-28 CL CL2022003008A patent/CL2022003008A1/es unknown
-
2025
- 2025-06-20 JP JP2025104881A patent/JP2025128388A/ja active Pending
- 2025-10-21 IL IL324105A patent/IL324105A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20220354A (es) | Inhibidores de egfr | |
| CR20240147A (es) | Uso de un inhibidor de la ezh2 en la preparación de fármacos para el tratamiento del linfoma de linfocitos t | |
| ZA202206923B (en) | New methylquinazolinone derivatives | |
| MX2024000230A (es) | Inhibidores de cdk2. | |
| MX2021013981A (es) | Inhibidores de la cinasa aurora y usos de los mismos. | |
| ZA202104112B (en) | 15-pgdh inhibitor | |
| PH12021552805A1 (en) | Cdk inhibitors | |
| ZA202201503B (en) | Urea compound for antagonizing lpa1 receptor | |
| MX2020006799A (es) | Derivados de oxi-fluoropiperidina como inhibidor de cinasa. | |
| MX2020006708A (es) | Derivado de amino-fluoropiperidina como inhibidor de cinasa. | |
| ZA202213152B (en) | Novel acid secretion inhibitor and use thereof | |
| ZA202407806B (en) | Kif18a inhibitor and use thereof | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| SA523451905B1 (ar) | Cdk2 مركبات بيريميدينيل-بيرازول بها استبدال كمثبطات | |
| MX2020002430A (es) | Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1). | |
| MY199779A (en) | Pyrrolopyrimidine compound and use thereof | |
| JOP20210312A1 (ar) | أملاح مقبولة صيدلانياً من [2-(3- فلورو-5- ميثان سلفونيل فينوكسي) إيثيل ](بروبيل) أمين واستخداماتها | |
| MX2022012881A (es) | Inhibidores de replicacion del virus de inmunodeficiencia humana. | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| MX2024012267A (es) | Inhibidores de egfr | |
| PH12021551957A1 (en) | 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative | |
| PH12022552821A1 (en) | Processes for the preparation of a kinase inhibitor | |
| MY209356A (en) | A xinafoate salt of a jak inhibiting compound | |
| PH12022550529A1 (en) | Magl inhibitor, preparation method and use thereof | |
| PH12021552787A1 (en) | Tetracyclic compounds as cdc7 inhibitors |